Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ADMS Adamas Pharmaceuticals, Inc. daily Stock Chart
ADMS [NASD]
Adamas Pharmaceuticals, Inc.
Healthcare | Drugs - Generic | USA
statements
Index- P/E- EPS (ttm)-4.25 Insider Own1.50% Shs Outstand23.18M Perf Week23.34%
Market Cap124.94M Forward P/E- EPS next Y-2.69 Insider Trans-1.03% Shs Float- Perf Month43.35%
Income-116.60M PEG- EPS next Q-0.90 Inst Own91.50% Short Float- Perf Quarter-13.34%
Sales48.30M P/S2.59 EPS this Y-22.80% Inst Trans0.19% Short Ratio5.73 Perf Half Y-1.82%
Book/sh1.55 P/B3.48 EPS next Y31.50% ROA-50.90% Target Price22.22 Perf Year-58.54%
Cash/sh7.27 P/C0.74 EPS next 5Y40.40% ROE-150.00% 52W Range3.35 - 13.25 Perf YTD-36.89%
Dividend- P/FCF- EPS past 5Y-29.00% ROI-55.00% 52W High-59.32% Beta1.64
Dividend %- Quick Ratio7.10 Sales past 5Y-13.70% Gross Margin96.60% 52W Low60.90% ATR0.39
Employees141 Current Ratio7.30 Sales Q/Q67.10% Oper. Margin- RSI (14)64.56 Volatility15.66% 8.25%
OptionableYes Debt/Eq2.89 EPS Q/Q28.30% Profit Margin- Rel Volume0.82 Prev Close5.63
ShortableYes LT Debt/Eq2.85 EarningsNov 07 AMC Payout- Avg Volume576.68K Price5.39
Recom2.30 SMA2029.27% SMA506.33% SMA200-15.24% Volume470,338 Change-4.26%
Sep-30-19Downgrade BofA/Merrill Neutral → Underperform $9 → $5
Sep-09-19Initiated Cantor Fitzgerald Neutral $8
Mar-05-19Downgrade Mizuho Neutral → Underperform $11 → $5
Nov-05-18Downgrade Mizuho Buy → Neutral
Oct-05-18Downgrade BofA/Merrill Buy → Neutral
Jul-16-18Initiated H.C. Wainwright Buy $45
Apr-04-18Initiated Leerink Partners Outperform $31
Mar-27-18Initiated BofA/Merrill Buy $39
Nov-29-17Initiated Northland Capital Outperform $70
Nov-08-17Reiterated Noble Financial Buy $33 → $48
Oct-30-17Initiated Evercore ISI Outperform $85
Sep-29-17Resumed Noble Financial Buy $33
Sep-19-17Reiterated Mizuho Buy $26 → $48
Aug-25-17Reiterated JMP Securities Mkt Outperform $29 → $33
Sep-08-16Reiterated Mizuho Buy $22 → $26
Jun-17-16Initiated Noble Financial Buy $25
Jun-16-16Upgrade Mizuho Neutral → Buy $22
May-12-16Reiterated Mizuho Neutral $17 → $16
Apr-28-16Reiterated Mizuho Neutral $14 → $17
Apr-01-16Initiated JMP Securities Mkt Outperform
Nov-08-19 04:01PM  Adamas Announces New Employment Inducement Grant GlobeNewswire +19.79%
08:14AM  The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Benzinga
Nov-07-19 06:55PM  Adamas Pharmaceuticals (ADMS) Reports Q3 Loss, Lags Revenue Estimates Zacks +5.38%
04:03PM  Adamas Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-04-19 11:01AM  What's in the Offing for Humana's (HUM) Earnings in Q3? Zacks
Oct-31-19 10:34AM  Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Oct-30-19 04:30PM  Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019 GlobeNewswire
Oct-28-19 06:21AM  Can We See Significant Institutional Ownership On The Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Share Register? Simply Wall St.
Oct-08-19 04:03PM  Adamas Announces New Employment Inducement Grant GlobeNewswire -10.71%
Oct-03-19 11:39PM  Edited Transcript of ADMS earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-27-19 04:05PM  Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference GlobeNewswire -5.39%
Sep-20-19 08:00AM  Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinsons Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress GlobeNewswire +8.59%
Sep-17-19 04:15PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Sep-13-19 07:51AM  Easy Come, Easy Go: How Adamas Pharmaceuticals (NASDAQ:ADMS) Shareholders Got Unlucky And Saw 71% Of Their Cash Evaporate Simply Wall St.
07:30AM  Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer GlobeNewswire
Sep-10-19 04:15PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Aug-12-19 05:07PM  Adamas Announces New Employment Inducement Grant GlobeNewswire +5.79%
03:11AM  Adamas Pharmaceuticals Inc (ADMS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 04:02PM  Adamas Reports Second Quarter 2019 Financial Results GlobeNewswire
11:11AM  Need To Know: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Insiders Have Been Selling Shares Simply Wall St.
Aug-01-19 10:33AM  Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-29-19 09:43AM  What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings? Zacks
Jul-23-19 04:05PM  Adamas to Announce Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019 GlobeNewswire
Jul-08-19 04:29PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
09:24AM  Top Ranked Momentum Stocks to Buy for July 8th Zacks
Jul-05-19 08:35AM  Bausch Gains 38.9% YTD on Product Launches & Debt Reduction Zacks
Jun-28-19 08:37PM  Hedge Funds Are Dumping Adamas Pharmaceuticals Inc (ADMS) Insider Monkey
06:50PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Jun-27-19 12:00PM  Lifshitz & Miller LLP Announces Investigation of Adamas Pharmaceuticals, Inc., ASGN Incorporated, Box, Inc., ChinaCache International Holdings Ltd, Mammoth Energy Services, Inc., Realogy Holdings Corp., Total System Services, Inc., and Verint Systems Inc. PR Newswire
Jun-26-19 03:10PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Jun-25-19 08:10AM  Will Adamas Pharmaceuticals Continue to Surge Higher? Zacks
Jun-21-19 10:37AM  Bausch Health (BHC) Catches Eye: Stock Jumps 6.2% Zacks
Jun-20-19 09:56AM  Should You Worry About Adamas Pharmaceuticals, Inc.'s (NASDAQ:ADMS) CEO Salary Level? Simply Wall St. +8.33%
09:51AM  Allergan (AGN) in Focus: Stock Moves 6.2% Higher Zacks
Jun-19-19 07:51AM  The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut Benzinga
Jun-18-19 04:05PM  Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinsons Disease GlobeNewswire
11:42AM  Edited Transcript of ADMS earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
09:00AM  What Makes Adamas (ADMS) a New Buy Stock Zacks
Jun-17-19 05:54PM  ADMS INVESTORS NOTICE: Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc. Business Wire +5.07%
05:23PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc. GlobeNewswire
Jun-12-19 08:20PM  INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
07:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
Jun-11-19 01:00PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE -6.94%
Jun-10-19 07:02PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS ACCESSWIRE
02:15PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
09:00AM  ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc. Business Wire
Jun-07-19 06:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS ACCESSWIRE
05:30PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Jun-04-19 11:49AM  ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire +8.37%
Jun-03-19 08:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS ACCESSWIRE
06:00PM  ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.s January 24, 2018 Secondary Public Offering To Contact The Firm ACCESSWIRE
04:31PM  Adamas to Present at Upcoming JMP Investor Conference GlobeNewswire
May-31-19 11:45AM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
May-30-19 07:03PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
06:31PM  ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.s January 24, 2018 Secondary Public Offering To Contact The Firm GlobeNewswire
04:30PM  Adamas Pharmaceuticals Welcomes Vijay Shreedhar as Chief Commercial Officer GlobeNewswire
May-29-19 10:32AM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:23AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adamas Pharmaceuticals, Inc. (ADMS) ACCESSWIRE
May-28-19 09:00PM  Bragar Eagel & Squire, P.C. is Investigating Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) on Behalf of Adamas Stockholders and Encourages Adamas Investors to Contact the Firm GlobeNewswire
05:55PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc. GlobeNewswire
03:58PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
02:28PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Adamas Pharmaceuticals, Inc. ADMS Business Wire
May-24-19 08:17PM  ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.'s January 24, 2018 Secondary Public Offering To Contact The Firm PR Newswire
04:08PM  EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc. GlobeNewswire
May-23-19 05:44PM  Robbins Arroyo LLP: Complaint Alleges that Adamas Pharmaceuticals Inc. (ADMS) Misled Shareholders Business Wire
May-14-19 09:00AM  Adamas (ADMS) Upgraded to Buy: Here's Why Zacks
May-13-19 11:14AM  Adamas to Present at Upcoming BAML Investor Conference GlobeNewswire
May-09-19 07:05PM  Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:02PM  Adamas: 1Q Earnings Snapshot Associated Press
04:03PM  Adamas Reports First Quarter 2019 Financial Results GlobeNewswire
May-06-19 09:39PM  Adamas Announces Data Presentations at the 71st American Academy of Neurology Annual Meeting GlobeNewswire
Apr-25-19 10:34AM  Will Adamas Pharmaceuticals (ADMS) Report Negative Q1 Earnings? What You Should Know Zacks
Apr-22-19 03:00PM  New Electric Vehicles Contain Much More Lithium Oilprice.com
02:46PM  Before You Buy Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), Consider Its Volatility Simply Wall St.
Mar-12-19 04:05PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Mar-08-19 02:49PM  Edited Transcript of ADMS earnings conference call or presentation 4-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-05-19 12:40PM  Why Adamas Pharmaceuticals Shares Are Crashing Today Motley Fool -32.84%
07:24AM  The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings Benzinga
Mar-04-19 09:34PM  Adamas Pharmaceuticals Inc (ADMS) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:35PM  Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018 GlobeNewswire
Feb-26-19 09:41AM  Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4? Zacks
Feb-21-19 10:31AM  Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Zacks
Feb-20-19 04:50PM  Adamas to Present at Two Upcoming Investor Conferences GlobeNewswire +5.24%
04:49PM  Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019 GlobeNewswire
09:32AM  Tenet Healthcare (THC) Q4 Earnings: What's in the Offing? Zacks
08:18AM  Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings? Zacks
Feb-18-19 08:18AM  AptarGroup (ATR) to Report Q4 Earnings: What's in Store? Zacks
07:25AM  Milacron (MCRN) to Report Q4 Earnings: What's in Store? Zacks
Feb-12-19 02:26PM  Should You Be Worried About Insider Transactions At Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)? Simply Wall St.
Feb-08-19 06:49PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
Feb-07-19 10:34AM  Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings? Zacks
08:15AM  Report: Exploring Fundamental Drivers Behind Roku, AECOM, 1-800 FLOWERS.COM, Eldorado Resorts, Haverty Furniture Companies, and Adamas Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-01-19 11:30AM  LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index ACCESSWIRE
Jan-10-19 04:30PM  Adamas Announces New Employment Inducement Grant GlobeNewswire
10:49AM  Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December Motley Fool
Jan-06-19 11:38AM  Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI Sales Results and Outlines Key Priorities for 2019 GlobeNewswire
Dec-19-18 07:46AM  The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas Benzinga
Dec-18-18 04:30PM  Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI GlobeNewswire -7.74%
Dec-17-18 09:43PM  Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy? Insider Monkey -5.59%
Dec-11-18 03:29PM  Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November Motley Fool
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MERRIWEATHER ALFRED GChief Financial OfficerSep 20Sale6.911,58410,94548,019Sep 23 04:19 PM
MAHONEY DAVID LDirectorSep 17Option Exercise1.7633,33258,49857,153Sep 18 04:38 PM
Prentiss Christopher BChief Accounting OfficerJul 22Sale6.001,0826,49247,209Jul 23 06:06 PM
Rhodes Jennifer JCBO, GC & Compliance OfficerJun 20Sale5.359405,02963,114Jun 21 05:38 PM
Rhodes Jennifer JCBO, GC & Compliance OfficerMar 20Sale7.991,79214,31831,612Mar 21 04:39 PM
Went Gregory TChief Executive OfficerMar 20Sale7.996,31950,489176,291Mar 21 04:37 PM
MERRIWEATHER ALFRED GChief Financial OfficerMar 20Sale7.998576,84724,603Mar 21 04:47 PM
Patni RajivChief Medical OfficerMar 20Sale8.002,37418,99219,141Mar 21 04:45 PM
Prentiss Christopher BChief Accounting OfficerMar 20Sale8.001,1859,48029,541Mar 21 04:43 PM
Rhodes Jennifer JCBO, GC & Compliance OfficerDec 20Sale7.524253,19633,404Dec 21 04:47 PM
Prentiss Christopher BChief Accounting OfficerDec 20Sale7.512281,71218,226Dec 26 05:09 PM
open in yahoo | open in reuters | open in google